ADC Therapeutics Beats Q2 2026 Estimates as Shares Decline
ADC Therapeutics surpassed second-quarter 2026 financial estimates, though company shares traded lower following the earnings announcement.
PA
Priya Anand · Equities & Earnings Desk · 15 Aug 2026 · 1 min read
ADC Therapeutics reported its second-quarter 2026 financial results, exceeding consensus analyst estimates for the period. Despite outperforming expectations on key financial metrics, the company's stock price experienced a decline in market trading following the release.
Additional details regarding specific revenue figures, earnings per share, and forward-looking guidance were outlined during the company's earnings call transcript.
This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
PA
Written by
Priya Anand
Equities & Earnings Desk
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →